Chengxia Kan

927 total citations
46 papers, 518 citations indexed

About

Chengxia Kan is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Chengxia Kan has authored 46 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 14 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Epidemiology. Recurrent topics in Chengxia Kan's work include Diabetes Treatment and Management (6 papers), Metabolism, Diabetes, and Cancer (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). Chengxia Kan is often cited by papers focused on Diabetes Treatment and Management (6 papers), Metabolism, Diabetes, and Cancer (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). Chengxia Kan collaborates with scholars based in China, United States and Australia. Chengxia Kan's co-authors include Xiaodong Sun, Ningning Hou, Fang Han, Kexin Zhang, Junfeng Shi, Yongping Liu, Na Qu, Yanhui Ma, Jingwen Zhang and Hongyan Qiu and has published in prestigious journals such as Biochemical and Biophysical Research Communications, International Journal of Biological Macromolecules and Behavioural Brain Research.

In The Last Decade

Chengxia Kan

39 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chengxia Kan China	13	193	99	91	85	54	46	518
Vanessa Marchant Spain	12	244 1.3×	65 0.7×	72 0.8×	52 0.6×	97 1.8×	25	658
Xiaozhen Tan China	13	269 1.4×	64 0.6×	55 0.6×	78 0.9×	39 0.7×	27	504
Xiaomu Kong China	15	240 1.2×	171 1.7×	93 1.0×	109 1.3×	157 2.9×	42	717
Min Hee Kim South Korea	8	286 1.5×	85 0.9×	111 1.2×	68 0.8×	68 1.3×	23	660
Jiaqi Chen China	15	279 1.4×	122 1.2×	124 1.4×	105 1.2×	51 0.9×	54	692
Parveen Jahan India	20	165 0.9×	99 1.0×	53 0.6×	45 0.5×	115 2.1×	63	918
Yan Shen China	12	159 0.8×	124 1.3×	76 0.8×	83 1.0×	48 0.9×	41	654
Hideyuki Kabasawa Japan	11	176 0.9×	85 0.9×	42 0.5×	79 0.9×	65 1.2×	34	553
Hanna Myśliwiec Poland	16	262 1.4×	49 0.5×	77 0.8×	145 1.7×	50 0.9×	50	707
Xiaofei An China	10	373 1.9×	120 1.2×	105 1.2×	103 1.2×	73 1.4×	19	690

Countries citing papers authored by Chengxia Kan

Since Specialization

Citations

This map shows the geographic impact of Chengxia Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengxia Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengxia Kan more than expected).

Fields of papers citing papers by Chengxia Kan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengxia Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengxia Kan. The network helps show where Chengxia Kan may publish in the future.

Co-authorship network of co-authors of Chengxia Kan

This figure shows the co-authorship network connecting the top 25 collaborators of Chengxia Kan. A scholar is included among the top collaborators of Chengxia Kan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengxia Kan. Chengxia Kan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kan, Chengxia, Kexin Zhang, Xiaofei Zhang, et al.. (2025). Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045. Annals of Hepatology. 30(2). 101898–101898. 8 indexed citations

Yu, Xiaohong, et al.. (2025). Flavonoids in Metabolic Disease: A Narrative Review of Mechanisms and Therapeutic Potential. Phytotherapy Research. 39(11). 5365–5377.

Fan, Qiming, et al.. (2025). Autophagy–senescence interplay in kidney disease: mechanistic insights and therapeutic potential. Molecular Biology Reports. 53(1). 22–22.

Kan, Chengxia, Kexin Zhang, Ningning Hou, et al.. (2025). Epidemiology of metabolic dysfunction-associated steatotic liver disease -related liver diseases: 1990–2021 and projections to 2045. European Journal of Gastroenterology & Hepatology. 38(2). 222–232.

Tang, Huiru, Chengxia Kan, Kexin Zhang, et al.. (2025). Glycerophospholipid and Sphingosine- 1-phosphate Metabolism in Cardiovascular Disease: Mechanisms and Therapeutic Potential. Journal of Cardiovascular Translational Research. 18(4). 749–761.

Zhang, Kexin, et al.. (2023). Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health. Frontiers in Public Health. 11. 1253506–1253506. 62 indexed citations

Song, Hongwei, Junfeng Shi, Yongping Liu, et al.. (2023). Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules. International Journal of Biological Macromolecules. 243. 125148–125148. 6 indexed citations

Zhang, Kexin, Jingwen Zhang, Chengxia Kan, et al.. (2023). Role of dysfunctional peri-organ adipose tissue in metabolic disease. Biochimie. 212. 12–20. 6 indexed citations

Li, Xuan, Bo Cao, Xinping Chen, et al.. (2023). Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease. International Urology and Nephrology. 56(2). 571–582. 5 indexed citations

10.

Ma, Yujie, Kexin Zhang, Junfeng Shi, et al.. (2023). Secreted frizzled-related protein 5: A promising therapeutic target for metabolic diseases via regulation of Wnt signaling. Biochemical and Biophysical Research Communications. 677. 70–76. 7 indexed citations

11.

Zhu, Liang, et al.. (2022). The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus. Cellular Reprogramming. 24(6). 329–342. 4 indexed citations

12.

Li, Xue, Xiaodong Sun, Chengxia Kan, et al.. (2022). COL1A1: A novel oncogenic gene and therapeutic target in malignancies. Pathology - Research and Practice. 236. 154013–154013. 62 indexed citations

13.

Zhang, Kexin, Yanhui Ma, Fang Han, et al.. (2022). Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019. Clinics and Research in Hepatology and Gastroenterology. 47(1). 102068–102068. 23 indexed citations

14.

Zhang, Kexin, et al.. (2022). The promotion of active aging through older adult education in the context of population aging. Frontiers in Public Health. 10. 998710–998710. 24 indexed citations

15.

Han, Fang, Chengxia Kan, Di Wu, et al.. (2022). Irisin protects against obesity-related chronic kidney disease by regulating perirenal adipose tissue function in obese mice. Lipids in Health and Disease. 21(1). 115–115. 15 indexed citations

16.

Ma, Yuting, Guangdong Zhang, Qian Xu, et al.. (2022). Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease. Frontiers in Pharmacology. 13. 944886–944886. 21 indexed citations

17.

Hou, Ningning, et al.. (2022). The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes. International Urology and Nephrology. 55(3). 617–629. 6 indexed citations

18.

Xu, Qian, Chengxia Kan, Ningning Hou, & Xiaodong Sun. (2022). Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report. World Journal of Clinical Cases. 10(6). 1909–1913.

19.

Hou, Ningning, Chengxia Kan, Na Huang, et al.. (2021). Relationship between serum Dickkopf-1 and albuminuria in patients with type 2 diabetes. World Journal of Diabetes. 12(1). 47–55. 3 indexed citations

20.

Kan, Chengxia, Yang Zhang, Fang Han, et al.. (2021). Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology. 12. 708494–708494. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact